Literature DB >> 26312673

Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent.

Maria Victória Quaresma1, Fred Bernardes Filho1, Janaína Hezel1, Murilo Calvo Peretti1, Bernard Kawa Kac1, Luna Azulay-Abulafia1.   

Abstract

Pemphigus vulgaris is an autoimmune disease characterized by suprabasal blisters with acantholysis, which has a fatal course in a large number of untreated patients. Systemic corticosteroid therapy is considered first-line therapy. Adjuvant treatment with the goal of sparing corticosteroids include, among others, dapsone. This drug is not without side effects and its use requires clinical and laboratory control. We present a patient with PV initially managed with suboptimal dose of prednisone, evolving into drug-induced hepatitis after introduction of dapsone.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26312673      PMCID： PMC4540507          DOI： 10.1590/abd1806-4841.20153408

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN： 0365-0596            Impact factor:   1.896


  9 in total

1.  A practical approach to treating autoimmune bullous disorders with systemic medications.

Authors:  Anne Han
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

2.  Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.

Authors:  Michael R Heaphy; Joerg Albrecht; Victoria P Werth
Journal:  Arch Dermatol       Date:  2005-06

3.  Dapsone hypersensitivity syndrome: a clinico-epidemiological review.

Authors:  Sudha Agrawal; Arun Agarwalla
Journal:  J Dermatol       Date:  2005-11       Impact factor: 4.005

4.  A retrospective study of the management of oral mucous membrane pemphigoid with dapsone.

Authors:  K N Ciarrocca; M S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-08

5.  Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.

Authors:  Victoria P Werth; David Fivenson; Amit G Pandya; Diana Chen; M Joyce Rico; Joerg Albrecht; David Jacobus
Journal:  Arch Dermatol       Date:  2008-01

6.  Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.

Authors:  Rachel Ash-Bernal; Robert Wise; Scott M Wright
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

Review 7.  Autoimmune bullous dermatoses.

Authors:  Paulo R Cunha; Silvia Regina C S Barraviera
Journal:  An Bras Dermatol       Date:  2009 Mar-Apr       Impact factor: 1.896

8.  Mycophenolate is effective in the treatment of pemphigus vulgaris.

Authors:  A H Enk; J Knop
Journal:  Arch Dermatol       Date:  1999-01

Review 9.  Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management.

Authors:  Crispian Scully; Stephen J Challacombe
Journal:  Crit Rev Oral Biol Med       Date:  2002
  9 in total
  3 in total

Review 1.  A comprehensive insight into the anti-inflammatory properties of dapsone.

Authors:  Mina Khalilzadeh; Maryam Shayan; Sina Jourian; Mohammad Rahimi; Mohammad Sheibani; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-20       Impact factor: 3.195

2.  Childhood pemphigus vulgaris is a challenging diagnosis.

Authors:  Gastão Tenório Lins; Nathalia Lages Sarmento Barbosa; Eulina Maria Vieira de Abreu; Klinger Vagner Teixeira da Costa; Kelly Chrystine Barbosa Meneses; Rodrigo Neves Silva; Sonia Maria Soares Ferreira
Journal:  Autops Case Rep       Date:  2021-04-30

3.  Vanishing bile duct syndrome arising in a patient with HIV infection sequentially treated with trimethoprim/sulfamethoxazole and dapsone.

Authors:  Pradeep Reddy Kathi; Maher Tama; Murray Ehrinpreis; Milton Mutchnick; Maria Westerhoff; Jonathan Mowers; Robert John Fontana
Journal:  Clin J Gastroenterol       Date:  2019-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.